hemophilia A

Hello, and welcome to today's episode of the ISTH Pulse podcast, where we'll be discussing next-generation factor memetics.

So looking back, the approval of Emesuzumab revolutionized care for patients with Haemophilia A.

For the first time, these patients had the opportunity to switch from factor prophylaxis to a factor memetics.

But

It was published on September 9, 2026, in the last couple of days.

The problem, factor VIII replacement transformed hemophilia A care, but requires frequent IV infusions and can be neutralized by inhibitors.

The big idea was emicizumab, a bispecific antibody that bridges factor IXa and factor X, functionally mimicking factor VIIIa without structurally resembling it.

How was it built? About 40,000 bispecific candidates were screened.